EOD vs RILY

The deterministic health profile is severely compromised with a Piotroski F-Score of 1/9, indicating critical weakness in traditional financial health metrics. However, this is contrasted by a strong valuation profile, with the current price of $6.31 trading at a significant discount to its intrinsic value of $9.87 and a very low P/E of 4.48. While long-term price performance is robust (5Y +85.8%), the current technical trend is heavily bearish (10/100). The asset functions as a high-yield income vehicle rather than a growth company, making traditional corporate health scores misleading but mandatory for this risk assessment.

RILY exhibits severe financial instability, highlighted by a weak Piotroski F-Score of 2/9 and a critical negative Price-to-Book ratio of -0.92, indicating negative shareholders' equity. While the P/E ratio of 1.04 and high YoY revenue growth (75.8%) appear attractive on the surface, they are likely value traps given the company's erratic earnings history and lack of fundamental health. The absence of an Altman Z-Score and Graham Number further underscores the inability to apply standard valuation models to this distressed balance sheet. Despite a recent 1-year price surge, the long-term trend is deeply negative, and the financial foundation is precarious.